ArticleBirth defects research2025
Teratogenic Effects of Serotonin Receptor 2B Disruption on the Migration and Cardiac Derivatives of the Cardiac Neural Crest.
Article in Birth defects research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Teratogenic Effects of Serotonin Receptor 2B Disruption on the Migration and Cardiac Derivatives of the Cardiac Neural Crest.Birth defects research · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
backgroundCardiac neural crest cells (cNCCs) are critical for heart development, and their disruption can result in congenital heart defects. Serotonin (5-HT) signaling, specifically via 5-HT2B and 5-HT2C receptors, regulates diverse physiological processes, including neural crest migration. This study investigates how modulation of 5-HT2B and 5-HT2C receptor activity impacts cNCC migration and the development of their derivatives, with relevance to serotonergic drug safety during pregnancy.
methodsChicken embryos at HH8 were treated with 50 μL of 20 μM 1-Methylpsilocin (1-MP), an inverse agonist of 5-HT2B and agonist of 5-HT2C, and collected at HH14 to assess cNCC migration. Embryos were pre-treated with SB242084, a selective 5-HT2C antagonist, to isolate receptor-specific contributions before 1-MP application. Phenotypic outcomes were assessed at HH32 and HH36 for structural heart defects.
results1-MP disrupted cNCC migration at HH14, evidenced by abnormal shortening of the circumpharyngeal neural crest (CirNCC) stream. Pre-treatment with SB242084 did not rescue the phenotype, implicating 5-HT2B as the primary driver, though potential contributions from 5-HT2C cannot be excluded. At HH32, 1-MP-treated embryos displayed gaps in the aorticopulmonary septum. By HH36, interventricular septal defects and delayed development further supported the role of 5-HT2B in cNCC migration and differentiation.
conclusionThese findings reveal that 5-HT2B receptor activity is critical for cNCC migration and heart development. They underscore the potential teratogenic risks of serotonergic drugs targeting 5-HT2B/5-HT2C receptors during pregnancy, with implications for drug safety and heart morphogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.